It is intended to provide a monoclonal antibody which specifically recognizes RGD in the amino acid sequence of human and mouse extracellular matrix proteins. By specifically inhibiting the adhesion mediated by the RGD sequence, it is expected that efficacious effects can be exerted on diseases such as inflammation, cancer, infection, autoimmunity and osteoporosis and side effects can be relieved at the same time. Thus, an improved therapy for these diseases can be provided.
